TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26162251

Group type: EXPERIMENTAL
Intervention: 2.5% Sodium Hypochlorite with positive pressure irrigation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.5% Sodium Hypochlorite with negative pressure irrigation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 25195020

Group type: EXPERIMENTAL
Intervention: Treatment according to the GermanIMPACT model
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as usual (control arm)
Number of subjects: 300
Study: 22765965

Group type: EXPERIMENTAL
Intervention: Trabectedin with pegylated liposomal doxorubicin (PLD)
Number of subjects: 663

Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Trabectedin with PLD
Number of subjects: 663
Study: 20029509

Group type: EXPERIMENTAL
Intervention: Chocolate milk (CHOC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbohydrate replacement beverage (CRB)
Number of subjects: 10
Study: 16461202

Group type: EXPERIMENTAL
Intervention: Indapamide SR (1.5 mg)
Number of subjects: 1758

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg)
Number of subjects: 1758

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1758
Study: 15290740

Group type: EXPERIMENTAL
Intervention: Semiflexed metatarsophalangeal (MTP) knee position
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 402
Study: 11403810

Group type: EXPERIMENTAL
Intervention: Testosterone and letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone and placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 9215015

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) for 10 days
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 7956751

Group type: EXPERIMENTAL
Intervention: MK-212 (20 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2455104

Group type: EXPERIMENTAL
Intervention: PN 200-110 at 3.8 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PN 200-110 at 5.7 mg b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pindolol 10 mg per day
Number of subjects: 20
Study: 30646316

Group type: EXPERIMENTAL
Intervention: Postrandomization consent pragmatic trial
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Traditional framing in high-stakes scenario
Number of subjects: 2004

Group type: COMPARATOR
Intervention: New framing in high-stakes scenario
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Traditional framing in low-stakes scenario
Number of subjects: 2004

Group type: COMPARATOR
Intervention: New framing in low-stakes scenario
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Better understanding of postrandomization consent design
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Personal involvement in control arm
Number of subjects: 2004
Study: 28397984

Group type: EXPERIMENTAL
Intervention: 12-month multifactorial intervention by primary care nurses including motivational interviews and individualized physical activity prescriptions.
Number of subjects: 368

Group type: COMPARATOR
Intervention: Usual practice (control group).
Number of subjects: 368
Study: 26187089

Group type: EXPERIMENTAL
Intervention: Friends Helping Friends program (treatment group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 23993298

Group type: EXPERIMENTAL
Intervention: VesCell therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 21166564

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel LC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional diathermy LC
Number of subjects: 40
Study: 18511864

Group type: EXPERIMENTAL
Intervention: Mean Platelet Volume (MPV)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Platelet Size Deviation Width (PDW)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Platelet-to-Large-Cell Ratio (P-LCR)
Number of subjects: 134
Study: 14963801

Group type: EXPERIMENTAL
Intervention: Rehabilitation allocation method
Number of subjects: 100
Study: 11642629

Group type: EXPERIMENTAL
Intervention: 9-valent conjugate pneumococcal vaccine (conjugated to CRM197)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control vaccine (conjugate meningococcus C vaccine, conjugated to CRM197)
Number of subjects: 264
Study: 9767199

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg max dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Methadone (60 mg equivalent, free dosing schedule)
Number of subjects: 34
Study: 7982295

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 20
Study: 2606882

Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 1116357

Group type: EXPERIMENTAL
Intervention: Headphones with stereophonic music
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 3
Study: 30640206

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.5 g per day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 141
Study: 28260993

Group type: EXPERIMENTAL
Intervention: Endoscopic mask
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nasal catheter
Number of subjects: 134
Study: 25277673

Group type: EXPERIMENTAL
Intervention: Graphical formats (line, pie, bar, or pictograph) with varying numerical information (no numbers, 1 number, or 2 numbers)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Line charts
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Pie charts
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Pictographs
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Bar charts
Number of subjects: 420
Study: 24262416

Group type: EXPERIMENTAL
Intervention: Balters bionator (Group 1: 6 children, 7-8 years; Group 2: 10 children, 9-10 years)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (7 children, 8-9 years)
Number of subjects: 23
Study: 22112008

Group type: EXPERIMENTAL
Intervention: Pro-recovery intervention (treatment as usual plus recovery-promoting relationships and working practices)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Pro-recovery intervention
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control
Number of subjects: 435
Study: 18940896

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 370
Study: 16968570

Group type: EXPERIMENTAL
Intervention: IL‐12/23 monoclonal antibody (0.3, 0.75, 1.5, and 3.0 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15214873

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once-daily for 5 days
Number of subjects: 430

Group type: COMPARATOR
Intervention: Penicillin V 500 mg three-times-daily for 10 days (Control)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice-daily for 10 days (Control)
Number of subjects: 430
Study: 11291826

Group type: EXPERIMENTAL
Intervention: High thoracic SCI subjects
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low thoracic SCI subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-SCI subjects
Number of subjects: 3
Study: 9296504

Group type: EXPERIMENTAL
Intervention: New bile diversion procedure with highly selective vagotomy, antireflux procedure, and duodenal switch procedure
Number of subjects: 65
Study: 8347731

Group type: EXPERIMENTAL
Intervention: Ubenimex (30 mg orally once a day during maintenance therapy)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 195
Study: 2872805

Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29294356

Group type: EXPERIMENTAL
Intervention: Deep breathing for 5 minutes (DB5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Deep breathing for 9 minutes (DB9)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Deep breathing for 7 minutes (DB7)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 50
Study: 27519185

Group type: COMPARATOR
Intervention: Standard model of service provision at the entry point (N=1319)
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Enhanced counseling and referral to add-on service with follow-up (N=1323)
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Components of study arm two with the additional offer of an escort (N=1321)
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 3963
Study: 24103187

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 21
Study: 22302530

Group type: EXPERIMENTAL
Intervention: Vitamin E administration (400 IU/day p.o.)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no Vitamin E)
Number of subjects: 103
Study: 20167238

Group type: EXPERIMENTAL
Intervention: High-fat breakfast (HF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-fat isoenergetic breakfast (LFE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-fat equal mass breakfast (LFM)
Number of subjects: 9
Study: 18390977

Group type: EXPERIMENTAL
Intervention: Canalith repositioning manoeuvre and vestibular stimulated exercise training three times a week for four weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Canalith repositioning manoeuvre
Number of subjects: 26
Study: 15941781

Group type: EXPERIMENTAL
Intervention: Energy restriction for 3 months designed to reduce body weight by 5-10%
Number of subjects: 16
Study: 11772419

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9459535

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8
Study: 7787467

Group type: EXPERIMENTAL
Intervention: Optimal therapy for acute myocardial infarction
Number of subjects: 0
Study: 2671517

Group type: EXPERIMENTAL
Intervention: Nonloading exercise program for back extensor muscles
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 65
Study: 820214

Group type: EXPERIMENTAL
Intervention: Coarse mesh gauze, changed three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formalinized xenograft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cadaver allograft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Porcine xenograft
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coarse mesh gauze
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biologic dressings
Number of subjects: 20
Study: 30458234

Group type: EXPERIMENTAL
Intervention: Hypofractionation (19 fractions of 3.4 Gy)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Conventional fractionation (39 fractions of 2.0 Gy)
Number of subjects: 820
Study: 29025483

Group type: EXPERIMENTAL
Intervention: Combination intervention package
Number of subjects: 371

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 371
Study: 26165773

Group type: EXPERIMENTAL
Intervention: Allicin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 48
Study: 23377862

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22048090

Group type: EXPERIMENTAL
Intervention: Postoperative cooling and compression
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no cooling and compression)
Number of subjects: 40
Study: 19197823

Group type: EXPERIMENTAL
Intervention: Symbioflor-2 (Escherichia coli product)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 16478902

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tetracaine plus Morphine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Tetracaine
Number of subjects: 132
Study: 12734762

Group type: EXPERIMENTAL
Intervention: Maprotiline 60 mg daily for 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 12
Study: 17310047

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (continuous insulin infusion to maintain intraoperative glucose levels between 4.4 and 5.6 mmol/L)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional treatment (no insulin unless glucose > 11.1 mmol/L)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 400
Study: 10755315

Group type: EXPERIMENTAL
Intervention: Cisplatin (70 mg/m2 on day 1), ifosfamide (1.5 g/m2 on days 1-4), irinotecan (60 mg/m2 on days 1, 8, and 15), with rhG-CSF (1 microg/kg on days 5-18)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2)
Number of subjects: 46
Study: 8891856

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg 3 times daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 2049963

Group type: EXPERIMENTAL
Intervention: Oral absorbable antibiotics (ofloxacin 400 mg/day and amoxicillin 20 g/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral nonabsorbable antibiotics (vancomycin 450 mg/day, tobramycin 450 mg/day, and colistin 4.5 x 10^6 units daily)
Number of subjects: 44
Study: 6658041

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study: 28373199

Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg intravenous every 12 hours (q12h)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg intravenous every 8 hours (q8h)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg intravenous every 12 hours (q12h)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 122
Study: 27048534

Group type: EXPERIMENTAL
Intervention: Screen-detected CRC
Number of subjects: 133

Group type: COMPARATOR
Intervention: Symptomatic CRC
Number of subjects: 133
Study: 25561129

Group type: EXPERIMENTAL
Intervention: Periodized water exercise training program (12 weeks, 5 times a week, 30 minutes, heart rate reserve 40-50% for weeks 1-6, 50-60% for weeks 7-12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 22584091

Group type: EXPERIMENTAL
Intervention: Nicotine gum and counseling for smoking cessation
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study: 21059621

Group type: EXPERIMENTAL
Intervention: Bojungikki-tang (TJ-41)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40
Study: 17931461

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of Vildagliptin 100 mg and Simvastatin 80 mg
Number of subjects: 24
Study: 15826726

Group type: EXPERIMENTAL
Intervention: Cirrhotic ALD patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-cirrhotic ALD patients
Number of subjects: 40
Study: 12474486

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 9497178

Group type: EXPERIMENTAL
Intervention: 10.2 g psyllium seed husk (PSH)/d
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control (0 g PSH/d)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 3.4 g psyllium seed husk (PSH)/d
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 6.8 g psyllium seed husk (PSH)/d
Number of subjects: 286
Study: 7710954

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) 20 mg orally daily starting 7 days before tamoxifen (TMX)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tamoxifen (TMX) 20 mg orally daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 14
Study: 2569105

Group type: EXPERIMENTAL
Intervention: Xamoterol plus amiodarone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metoprolol plus amiodarone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 6
Study: 31622472

Group type: EXPERIMENTAL
Intervention: Training with sleep after a 12-hour interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training with wakefulness after a 12-hour interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with a nap and polysomnography monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sigma activity during NREM sleep
Number of subjects: 0
Study: 30511934

Group type: EXPERIMENTAL
Intervention: PA projection
Number of subjects: 100

Group type: COMPARATOR
Intervention: AP projection
Number of subjects: 100
Study: 27208831

Group type: EXPERIMENTAL
Intervention: tDCS of left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: tDCS of left primary motor cortex (M1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study: 24384657

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21687979

Group type: EXPERIMENTAL
Intervention: SRP and irrigation with toluidine blue O (TBO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SRP, irrigation with TBO and low‐level laser irradiation (PDT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 33
Study: 19653740

Group type: EXPERIMENTAL
Intervention: Pose training through a face-name association task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Illumination training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced level of pose training
Number of subjects: 0
Study: 17879543

Group type: EXPERIMENTAL
Intervention: Qingbi Tablet (Chinese herbal preparation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisone (lesser dosage in treated group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group treatment (amethopterin, voltaren, hydroxychloroquine)
Number of subjects: 120
Study: 15672845

Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (7%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulised isotonic saline (0.9%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active cycle breathing technique (ACBT) alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulised terbutaline, nebulised IS then ACBT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nebulised terbutaline, nebulised HS then ACBT
Number of subjects: 24
Study: 12171641

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtxA) - 500 units injected into the biceps brachii of the paretic arm
Number of subjects: 8
Study: 10524663

Group type: EXPERIMENTAL
Intervention: Acetaminophen, aspirin, and caffeine (AAC)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1220
Study: 8538485

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo 500 mg/day (calcium)
Number of subjects: 28
Study: 1773148

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 96
Study: 7041086

Group type: EXPERIMENTAL
Intervention: ursodesoxycholic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: chenodesoxycholic acid
Number of subjects: 0
Study: 31887206

Group type: EXPERIMENTAL
Intervention: Domiciliary High-flow, humidified, nasal cannula (HFNC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study: 28693604

Group type: EXPERIMENTAL
Intervention: Right median nerve electrical stimulation (RMNS) at 15-20 mA, pulse width of 300 μs, 40 Hz ON for 20 s and OFF for 40 s, for 8 hours per day for 2 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Right median nerve electrical stimulation (RMNS)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Non-stimulation group
Number of subjects: 380
Study: 26444986

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 5 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 20 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 56
Study: 24386301

Group type: EXPERIMENTAL
Intervention: Training on camouflage search displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training on non-camouflage displays
Number of subjects: 0
Study: 22287376

Group type: EXPERIMENTAL
Intervention: 2 mL 0.25% bupivacaine with epinephrine 1:100,000 (BP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 60
Study: 19695030

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg administered at bedtime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Olmesartan 40 mg administered at morning
Number of subjects: 40
Study: 17767673

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 15581208

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isoniazid (INH) 300 mg without alcohol
Number of subjects: 10